Frequency of genetic polymorphism for adrenergic receptor beta and cytochrome p450 2D6 enzyme, and effects on tolerability of beta-blocker therapy in heart failure with reduced ejection fraction patients: The Beta GenTURK study
Yıl: 2016 Cilt: 44 Sayı: 6 Sayfa Aralığı: 457 - 465 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022
Frequency of genetic polymorphism for adrenergic receptor beta and cytochrome p450 2D6 enzyme, and effects on tolerability of beta-blocker therapy in heart failure with reduced ejection fraction patients: The Beta GenTURK study
Öz: Bu çalışmanın amacı, ejeksiyon fraksiyonu düşük olup kalp yetersizliği (KY) bulunan hastalarda Arginine389Glycine (Arg389Gly) ve sitokrom p450 2D6*10 (Cyp2D6*10) polimorfizmi sıklıklarını belirlemek ve bu polimorfizmlerin beta bloker (BB) tedavisi yanıtına etkisini değerlendirmektir.Yöntemler: Ejeksiyon fraksiyonu düşük olup KY bulunan 206 hasta ve sağlıklı 90 kişilik kontrol grubu ileriye dönük olarak çalışmaya dahil edildi. Kontrol grubunun tümünün, KY'li 206 hastanın ise 162'sinin Arg389Gly ve Cyp2D6*10 polimorfizmi için genotipleri, polimeraz zincir reaksiyon ve restriksiyon fragman uzunluk polimorfizmi analizi aracılığı ile belirlendi. Azalmış ejeksiyon fraksiyonlu KY'li hastalar ve sağlıklı kontroller Arg389Gly gen polimorfizmi açısından karşılaştırıldı. Ayrıca KY'li hastalar en yüksek BB hedef dozuna ulaşıp ulaşamamalarına göre iki gruba ayrıldı.Bulgular: Azalmış ejeksiyon fraksiyonlu KY'li hastalar ile sağlıklı kontroller arasında Arg389Gly polimorfizmi için genotip dağılım sıklıkları açısından yapılan karşılaştırmada CC ve GG genotipleri ile anlamlı ilişki gözlendi (p<0.001, OR=16, CI: 3.8-67.9 ve p<0.001, OR=0.3, CI: 0.2-0.6). En yüksek BB hedef dozuna ulaşan ve ulaşamayan hastaların ise Arg389Gly ve Cyp2D6*10 polimorfizmi için genotip sıklıkları benzerdir (sırasıyla, p=0.13, p=0.60).Sonuç: Bu seçilmiş Türk popülasyonunda Arg389Gly polimorfizmi sıklığı azalmış ejeksiyon fraksiyonlu KY'li hastalarda sağlıklı kontrol grubundan farklıdır. Ayrıca Arg389Gly ve Cyp2D6*10 polimorfizmi BB tolerabilitesi ile ilişkili değildir
Anahtar Kelime: Konular:
Kalp yetersizliği bulunan ejeksiyon fraksiyonu düşük hastalarda B1 adrenerjik reseptör ve sitokrom p450 2D6 enzimi genetik polimorfizmi sıklığı ve beta bloker tolerabilitesi üzerine etkisi: Beta GenTURK çalışması
Öz: The present objective was to determine frequency of Arginine389Glycine (Arg389Gly) and Cytochrome p450 2D6*10 (Cyp2D6*10) polymorphism in cases of heart failure-reduced ejection fraction (HFREF), and to evaluate the influence of the polymorphisms in response to beta-blocker (BB) therapy.Methods: A total of 206 HFREF patients and 90 healthy controls were prospectively enrolled. Genotypes for Arg389Gly and Cyp2D6*10 polymorphisms of the healthy controls and 162 of the 206 heart failure (HF) patients were measured, identified by polymerase-chain-reaction- and restriction-fragment-lengthpolymorphism analysis. HFREF patients and healthy controls were compared regarding Arg389Gly polymorphism. The HFREF patients were separated into 2 subgroups based on achievement of maximal target dose (MTD) of BB.Results: When comparing frequency of genotype distribution for Arg389Gly polymorphism in HFREF patients to the healthy controls, a statistically significant association was observed with CC genotype and Glisin-Glisin (GG) genotype (p<0.001, odds ratio [OR]=16, confidence interval [CI]: 3.8-67.9 and p<0.001, OR=0.3, CI: 0.2-0.6). Frequency of genotypes for Arg389Gly and Cyp2D6*10 polymorphism were similar in patients who could or could not achieve BB MTD (p=0.13 and p=0.60, respectively).Conclusion: The frequency of Arg389Gly polymorphism in patients with HFREF in the present Turkish population differed from that of the healthy controls. However, neither Arg389Gly polymorphism nor Cyp2D6*10 polymorphism was associated with dose tolerability of BB therapy
Anahtar Kelime: Konular:
Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
0
0
0
- Brodde OE, Michel MC. Adrenergic and muscarinic receptors in the human heart. Pharmacol Rev 1999;51:651-90.
- Packer M. Neurohormonal interactions and adaptations in congestive heart failure. Circulation 1988;77:721-30.
- Mann DL, Bristow MR. Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation 2005;111:2837-49.
- Bristow MR. Treatment of chronic heart failure with ?-adrenergic receptor antagonists: a convergence of re- ceptor pharmacology and clinical cardiology. Circ Res 2011;109:1176-94.
- Liggett SB, Mialet-Perez J, Thaneemit-Chen S, Weber SA, Greene SM, Hodne D, et al. A polymorphism within a con- served beta(1)-adrenergic receptor motif alters cardiac func- tion and beta-blocker response in human heart failure. Proc Natl Acad Sci U S A 2006;103:11288-93.
- Terra SG, Pauly DF, Lee CR, Patterson JH, Adams KF, Scho- field RS, et al. beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled re- lease/extended release in heart failure. Clin Pharmacol Ther 2005;77:127-37.
- de Groote P, Helbecque N, Lamblin N, Hermant X, Mc Fad- den E, Foucher-Hossein C, et al. Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure. Pharmacogenet Genomics 2005;15:137-42.
- Taylor MR, Bristow MR. The emerging pharmacogenom- ics of the beta-adrenergic receptors. Congest Heart Fail 2004;10:281-8.
- Liggett SB, Cresci S, Kelly RJ, Syed FM, Matkovich SJ, Hahn HS, et al. A GRK5 polymorphism that inhibits beta-ad- renergic receptor signaling is protective in heart failure. Nat Med 2008;14:510-7.
- Mason DA, Moore JD, Green SA, Liggett SB. A gain-of-func- tion polymorphism in a G-protein coupling domain of the hu- man beta1-adrenergic receptor. J Biol Chem 1999;274:12670- 4.
- the possibility to address genetic polymorphisms in
- Metra M, Zani C, Covolo L, Nodari S, Pezzali N, Gelatti U, et al. Role of beta1- and alpha2c-adrenergic receptor polymor- phisms and their combination in heart failure: a case-control study. Eur J Heart Fail 2006;8:131-5.
- Fragoso JM, Rodríguez-Pérez JM, González J, Cruz D, Pérez- Méndez O, de Jesus García J, et al. Beta1-adrenergic recep- tor gene polymorphisms in Mexican patients with idiopathic dilated cardiomyopathy. Exp Mol Pathol 2006;80:279-82.
- Canham RM, Das SR, Leonard D, Abdullah SM, Mehta SK, Chung AK, et al. Alpha2cDel322-325 and beta1Arg389 ad- renergic polymorphisms are not associated with reduced left ventricular ejection fraction or increased left ventricular vol- ume. J Am Coll Cardiol 2007;49:274-6.
- Paczkowska A, Szperl M, Malek L, Mazurkiewicz L, Skóra E, Grzybowski J, et al. Polymorphisms of the beta-1 and beta-2 adrenergic receptors in Polish patients with idiopathic dilated cardiomyopathy. Kardiol Pol 2009;67:235-41.
- Woodiwiss AJ, Badenhorst D, Sliwa K, Brooksbank R, Essop R, Sareli P, et al. Beta1- and alpha2c-adrenoreceptor variants as predictors of clinical aspects of dilated cardiomyopathy in people of African ancestry. Cardiovasc J Afr 2008;19:188-93.
- Nonen S, Okamoto H, Akino M, Matsui Y, Fujio Y, Yoshiyama M, et al. No positive association between adrenergic receptor variants of alpha2cDel322-325, beta1Ser49, beta1Arg389 and the risk for heart failure in the Japanese population. Br J Clin Pharmacol 2005;60:414-7.
- Biolo A, Clausell N, Santos KG, Salvaro R, Ashton-Prolla P, Borges A, et al. Impact of beta1-adrenergic receptor polymor- phisms on susceptibility to heart failure, arrhythmogenesis, prognosis, and response to beta-blocker therapy. Am J Cardiol 2008;102:726-32.
- Forleo C, Sorrentino S, Guida P, Romito R, De Tommasi E, Iacoviello M, et al. Beta1- and beta2-adrenergic receptor polymorphisms affect susceptibility to idiopathic dilated car- diomyopathy. J Cardiovasc Med (Hagerstown) 2007;8:589- 95.
- Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol pro- spective randomized cumulative survival (COPERNICUS) study. Circulation 2002;106:2194-9.
- Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, et al. Randomized trial to deter- mine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SE- NIORS). Eur Heart J 2005;26:215,25.
- Effect of metoprolol CR/XL in chronic heart failure: Meto- prolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) Lancet 1999;353:2001-7.
- Krum H, Ninio D, MacDonald P. Baseline predictors of tol- erability to carvedilol in patients with chronic heart failure. Heart 2000;84:615-9.
- Krum H, Hill J, Fruhwald F, Sharpe C, Abraham G, Zhu JR,
- ;25:1534-41. P450 2D6: overview and update on pharmacology, genet- ics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 2004;369:23-37.
- Zhou SF, Liu JP, Chowbay B. Polymorphism of human cy- tochrome P450 enzymes and its clinical impact. Drug Metab Rev 2009;41:89-295.
- Lefebvre J, Poirier L, Poirier P, Turgeon J, Lacourciere Y. The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension. Br J Clin Pharmacol 2007;63:575-82.
- Nikolic VN, Jankovic SM, Velickovic-Radovanovic R, Apostolovic S, Stanojevic D, Zivanovic S, et al. Population pharmacokinetics of carvedilol in patients with congestive heart failure. J Pharm Sci 2013;102:2851-8.
- with heart failure: a MERIT-HF sub-study. Eur J Heart Fail 2003;5:463-8.
- Van Peer A, Snoeck E, Woestenborghs R. Clinical pharma- cokinetics of nebivolol. A review. Drug Invest 1991;3(Suppl. 1):25-30.
- Zanger UM, Raimundo S, Eichelbaum M. Cytochrome
| APA | ZOGHİ M, Kaya H, Çavuşoğlu Y, Aksakal E, DEMİR Ş, YÜCEL C, MUTLU H, ERGENE O, YILMAZ M (2016). Frequency of genetic polymorphism for adrenergic receptor beta and cytochrome p450 2D6 enzyme, and effects on tolerability of beta-blocker therapy in heart failure with reduced ejection fraction patients: The Beta GenTURK study. , 457 - 465. |
| Chicago | ZOGHİ Mehdi,Kaya Hakkı,Çavuşoğlu Yüksel,Aksakal Enbiya,DEMİR Şerafettin,YÜCEL Ceyhun,MUTLU Haşim,ERGENE Oktay,YILMAZ MEHMET BIRHAN Frequency of genetic polymorphism for adrenergic receptor beta and cytochrome p450 2D6 enzyme, and effects on tolerability of beta-blocker therapy in heart failure with reduced ejection fraction patients: The Beta GenTURK study. (2016): 457 - 465. |
| MLA | ZOGHİ Mehdi,Kaya Hakkı,Çavuşoğlu Yüksel,Aksakal Enbiya,DEMİR Şerafettin,YÜCEL Ceyhun,MUTLU Haşim,ERGENE Oktay,YILMAZ MEHMET BIRHAN Frequency of genetic polymorphism for adrenergic receptor beta and cytochrome p450 2D6 enzyme, and effects on tolerability of beta-blocker therapy in heart failure with reduced ejection fraction patients: The Beta GenTURK study. , 2016, ss.457 - 465. |
| AMA | ZOGHİ M,Kaya H,Çavuşoğlu Y,Aksakal E,DEMİR Ş,YÜCEL C,MUTLU H,ERGENE O,YILMAZ M Frequency of genetic polymorphism for adrenergic receptor beta and cytochrome p450 2D6 enzyme, and effects on tolerability of beta-blocker therapy in heart failure with reduced ejection fraction patients: The Beta GenTURK study. . 2016; 457 - 465. |
| Vancouver | ZOGHİ M,Kaya H,Çavuşoğlu Y,Aksakal E,DEMİR Ş,YÜCEL C,MUTLU H,ERGENE O,YILMAZ M Frequency of genetic polymorphism for adrenergic receptor beta and cytochrome p450 2D6 enzyme, and effects on tolerability of beta-blocker therapy in heart failure with reduced ejection fraction patients: The Beta GenTURK study. . 2016; 457 - 465. |
| IEEE | ZOGHİ M,Kaya H,Çavuşoğlu Y,Aksakal E,DEMİR Ş,YÜCEL C,MUTLU H,ERGENE O,YILMAZ M "Frequency of genetic polymorphism for adrenergic receptor beta and cytochrome p450 2D6 enzyme, and effects on tolerability of beta-blocker therapy in heart failure with reduced ejection fraction patients: The Beta GenTURK study." , ss.457 - 465, 2016. |
| ISNAD | ZOGHİ, Mehdi vd. "Frequency of genetic polymorphism for adrenergic receptor beta and cytochrome p450 2D6 enzyme, and effects on tolerability of beta-blocker therapy in heart failure with reduced ejection fraction patients: The Beta GenTURK study". (2016), 457-465. |
| APA | ZOGHİ M, Kaya H, Çavuşoğlu Y, Aksakal E, DEMİR Ş, YÜCEL C, MUTLU H, ERGENE O, YILMAZ M (2016). Frequency of genetic polymorphism for adrenergic receptor beta and cytochrome p450 2D6 enzyme, and effects on tolerability of beta-blocker therapy in heart failure with reduced ejection fraction patients: The Beta GenTURK study. Türk Kardiyoloji Derneği Arşivi, 44(6), 457 - 465. |
| Chicago | ZOGHİ Mehdi,Kaya Hakkı,Çavuşoğlu Yüksel,Aksakal Enbiya,DEMİR Şerafettin,YÜCEL Ceyhun,MUTLU Haşim,ERGENE Oktay,YILMAZ MEHMET BIRHAN Frequency of genetic polymorphism for adrenergic receptor beta and cytochrome p450 2D6 enzyme, and effects on tolerability of beta-blocker therapy in heart failure with reduced ejection fraction patients: The Beta GenTURK study. Türk Kardiyoloji Derneği Arşivi 44, no.6 (2016): 457 - 465. |
| MLA | ZOGHİ Mehdi,Kaya Hakkı,Çavuşoğlu Yüksel,Aksakal Enbiya,DEMİR Şerafettin,YÜCEL Ceyhun,MUTLU Haşim,ERGENE Oktay,YILMAZ MEHMET BIRHAN Frequency of genetic polymorphism for adrenergic receptor beta and cytochrome p450 2D6 enzyme, and effects on tolerability of beta-blocker therapy in heart failure with reduced ejection fraction patients: The Beta GenTURK study. Türk Kardiyoloji Derneği Arşivi, vol.44, no.6, 2016, ss.457 - 465. |
| AMA | ZOGHİ M,Kaya H,Çavuşoğlu Y,Aksakal E,DEMİR Ş,YÜCEL C,MUTLU H,ERGENE O,YILMAZ M Frequency of genetic polymorphism for adrenergic receptor beta and cytochrome p450 2D6 enzyme, and effects on tolerability of beta-blocker therapy in heart failure with reduced ejection fraction patients: The Beta GenTURK study. Türk Kardiyoloji Derneği Arşivi. 2016; 44(6): 457 - 465. |
| Vancouver | ZOGHİ M,Kaya H,Çavuşoğlu Y,Aksakal E,DEMİR Ş,YÜCEL C,MUTLU H,ERGENE O,YILMAZ M Frequency of genetic polymorphism for adrenergic receptor beta and cytochrome p450 2D6 enzyme, and effects on tolerability of beta-blocker therapy in heart failure with reduced ejection fraction patients: The Beta GenTURK study. Türk Kardiyoloji Derneği Arşivi. 2016; 44(6): 457 - 465. |
| IEEE | ZOGHİ M,Kaya H,Çavuşoğlu Y,Aksakal E,DEMİR Ş,YÜCEL C,MUTLU H,ERGENE O,YILMAZ M "Frequency of genetic polymorphism for adrenergic receptor beta and cytochrome p450 2D6 enzyme, and effects on tolerability of beta-blocker therapy in heart failure with reduced ejection fraction patients: The Beta GenTURK study." Türk Kardiyoloji Derneği Arşivi, 44, ss.457 - 465, 2016. |
| ISNAD | ZOGHİ, Mehdi vd. "Frequency of genetic polymorphism for adrenergic receptor beta and cytochrome p450 2D6 enzyme, and effects on tolerability of beta-blocker therapy in heart failure with reduced ejection fraction patients: The Beta GenTURK study". Türk Kardiyoloji Derneği Arşivi 44/6 (2016), 457-465. |
